Treats deleterious or suspected deleterious germline BRCA … metastatic breast cancer. Sold as Talzenna. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Talazoparib Tosylate (sold as Talzenna), first approved Oct 16, 2018, with 9 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Talzenna | Part D | $124M | +108% | 1,254 |
| Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerProstate Cancer · M.D. Anderson Cancer Center | Phase 2 | Recruiting | May 24, 2023 |
| Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm · M.D. Anderson Cancer Center | Phase 1 | Recruiting | Jan 5, 2021 |
| Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal CancerAdvanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma · Roswell Park Cancer Institute | Phase 1 | Recruiting | Aug 12, 2020 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer